What did @elevatewithsydney actually say?
The transcript from this video is garbled and unreadable, likely a transcription error or audio processing failure. The caption, however, does the heavy lifting: she claims to have lost 13 pounds in two weeks on Wegovy after struggling with postpartum weight gain, and describes it as "truly changing my life." Those are the claims worth examining.
To be clear, the actual spoken content of this video cannot be verified from the transcript provided. What we can analyze are the specific claims made in the caption, which 144,600 viewers saw alongside the video. A caption on a health-related post is a claim whether or not it comes with a disclaimer. The framing, "nothing was working for me until," positions semaglutide as a solution that succeeded where everything else failed, which is a meaningful medical claim for a postpartum audience.
Does the science back this up?
Some of it, yes. Semaglutide does produce real weight loss. But 13 pounds in 14 days is well outside what the clinical data would predict, and the postpartum context raises specific concerns that nobody in the comments will bring up.
The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) showed an average weight loss of about 14.9% of body weight over 68 weeks in adults with obesity, not 14 days. Early losses in the first weeks are mostly water weight and reduced food volume, not fat. A 2022 review by Rubino et al. in JAMA also confirmed that weight loss with semaglutide is gradual and dose-dependent, with meaningful fat loss occurring over months.
On the postpartum angle: Wegovy is not approved for use in breastfeeding individuals, and Novo Nordisk explicitly excludes this population. The FDA label notes that animal studies show semaglutide passes into breast milk. If this creator is nursing, that is a clinical red flag that deserves more than a green heart emoji.
What did they get wrong (or right)?
They got the broad strokes right: semaglutide is a legitimate, FDA-approved option for weight management in adults with obesity or overweight with a related condition. It does work. Postpartum weight retention is a real, underaddressed medical issue, and dismissing it would be unfair.
But "already down 13 lbs" in two weeks is almost certainly misleading, even if the scale says so. Rapid early losses on GLP-1 agonists are heavily driven by reduced caloric intake, decreased gastric emptying, and fluid shifts, not meaningful fat loss. Reporting this number without that context sets a false expectation for everyone watching. Most people in clinical trials do not lose 13 pounds in two weeks. The STEP 4 trial (Rubino et al., 2021, JAMA) showed the drug's mechanism requires months to produce sustained results.
The framing of "nothing was working for me until" also flattens a complicated postpartum metabolic picture. Hormonal changes, sleep deprivation, and breastfeeding all affect weight independently. Attributing all progress to one drug after two weeks is premature at best.
What should you actually know?
Semaglutide is not a two-week fix, and anyone selling it that way, intentionally or not, is doing the audience a disservice. It is a weekly injectable that requires gradual dose escalation over months, and the real weight loss data comes from long-term adherence, not the first 14 days.
If you are postpartum and considering semaglutide, the clinical picture is genuinely complicated. Rapid caloric restriction postpartum can affect milk supply. Semaglutide is not studied in this population for safety. A prescriber who does not ask about breastfeeding status before prescribing is missing a critical step.
Beyond the postpartum issue, there is a real discontinuation risk. When people stop taking semaglutide, most of the weight returns. The STEP 4 extension data showed participants regained about two-thirds of lost weight within a year of stopping (Rubino et al., 2021, JAMA). Lifestyle change alongside the medication is what the clinical data actually supports for long-term results.
One more thing: Wegovy and Ozempic contain the same active ingredient but are approved for different indications. Compounded semaglutide is not equivalent to either branded product. These distinctions matter, and they get lost completely in hashtag-driven content like this.